Baxter International Reaches New 52-Week High (BAX)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Baxter International (NYSE: BAX) hit a new 52-week high Thursday as it is currently trading at $63.34, above its previous 52-week high of $63.05 with 294,565 shares traded as of 9:40 a.m. ET. Average volume has been 2.4 million shares over the past 30 days.

Baxter International has a market cap of $33.47 billion and is part of the health care sector and health services industry. Shares are up 23.6% year to date as of the close of trading on Wednesday.

Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company has a P/E ratio of 15.3, above the average health services industry P/E ratio of 14.9 and below the S&P 500 P/E ratio of 17.7.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, growth in earnings per share, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Baxter International Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

Should You Dump Johnson & Johnson for Baxter and Abbott?

Should You Dump Johnson & Johnson for Baxter and Abbott?

Medtronic's Strong Q1 Helps Send Healthcare Stocks Higher

Medtronic's Strong Q1 Helps Send Healthcare Stocks Higher

Puerto Rico's Once-Bustling Healthcare Industry Remains In Disarray

Puerto Rico's Once-Bustling Healthcare Industry Remains In Disarray

Edwards Lifesciences, AeroVironment, Oshkosh Truck: 'Mad Money' Lightning Round

Edwards Lifesciences, AeroVironment, Oshkosh Truck: 'Mad Money' Lightning Round

Beware This Bull Stampede: Cramer's 'Mad Money' Recap (Tuesday 10/3/17)

Beware This Bull Stampede: Cramer's 'Mad Money' Recap (Tuesday 10/3/17)